Sugi Predict

Sugi Predict / Compounds / SCHEMBL307760

SCHEMBL307760

SCHEMBL307760

OCc1ccc(Br)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PYCR1 P32322 1/20 0.46
▸ PTGDR2 Q9Y5Y4 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.39
▸ MAPK1 P28482 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ TSHR P16473 2/20 0.36
▸ SLC6A4 P31645 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SLC6A2 P23975 1/20 0.36
▸ IDO1 P14902 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30467771 1.00 PYCR1 (0.46) PYCR1PTGDR2ALDH1A1MAPK1SMN1; SMN2
Ammonia Solution, Strong SCHEMBL23833320 0.98 PYCR1 (0.45) PYCR1PTGDR2ALDH1A1MAPK1SMN1; SMN2
SCHEMBL589200 0.83 PYCR1 (0.44) PYCR1ALDH1A1MAPK1SMN1; SMN2RECQL
SCHEMBL154181 0.82 PTGDR2 (0.44) PYCR1PTGDR2ALDH1A1MAPK1SMN1; SMN2
SCHEMBL6299216 0.79 PYCR1 (0.47) PYCR1ALDH1A1MAPK1SMN1; SMN2TSHR
SCHEMBL307792 0.79 PYCR1 (0.47) PYCR1ALDH1A1MAPK1SMN1; SMN2TSHR
SCHEMBL30345107 0.79 PYCR1 (0.47) PYCR1ALDH1A1MAPK1SMN1; SMN2TSHR
SCHEMBL29417721 0.78 PTGDR2 (0.48) PTGDR2ALDH1A1MAPK1TSHRSLC6A4
SCHEMBL795719 0.78 PTGDR2 (0.48) PTGDR2ALDH1A1MAPK1TSHRSLC6A4
SCHEMBL31185565 0.77 PSEN1 (0.39) IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 — — US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 — — US disclosed
EP-4393919-A1 LSD1 MODULATORS Exscientia Al Limited (GB) 2024-07-03 — — EP disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 — — US disclosed
US-12016835-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2024-06-25 — — US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 — — CN disclosed
US-6348474-B1 COMPOUNDS AS ANTIDIABETIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 — — US disclosed
CN-1335837-A Imidazole compounds and medicinal use thereof FUJISAWA PHARMACEUTICAL CO (JP) 2002-02-13 — — CN disclosed
CN-1335847-A Sulfonamide compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO (JP) 2002-02-13 — — CN disclosed
EP-1142879-A1 IMIDAZOLE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 — — EP disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 — — EP disclosed
CN-1268942-A Sulfonamide compounds and medicinal use thereof FUJISAWA PHARMACEUTICAL CO (JP) 2000-10-04 — — CN disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 — — EP disclosed
EP-0328643-B1 (alpha)-HYDROPEROXYISOPROPYLPHENYL COMPOUNDS AND PROCESS FOR THEIR PREPARATION TERUMO CORP (JP) 1994-07-06 — — EP disclosed
US-5043142-A Measuring peroxide-active substances TERUMO KABUSHIKI KAISHA (JP) 1991-08-27 — — US disclosed
EP-0328643-A1 (alpha)-HYDROPEROXYISOPROPYLPHENYL COMPOUNDS AND PROCESS FOR THEIR PREPARATION TERUMO KABUSHIKI KAISHA (JP) 1989-08-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PYCR1 1729/4885PTGDR2 2072/4885ALDH1A1 653/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 PYCR1 1729/4885PTGDR2 2072/4885ALDH1A1 653/4885
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP PYCR1 1317/4885PTGDR2 3803/4885ALDH1A1 1182/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH PYCR1 3558/4885PTGDR2 3070/4885ALDH1A1 3178/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 PYCR1 2101/4885PTGDR2 1740/4885ALDH1A1 3094/4885
US-12016835-B2 Neprilysin inhibitors MME, REN, ACE PYCR1 4018/4885PTGDR2 3467/4885ALDH1A1 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.